Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration
Department of Research and Development, BRAHMS GmbH, Part of Thermo Fisher Scientific, 16761 Hennigsdorf, Germany
BMC Medicine 2011, 9:137 doi:10.1186/1741-7015-9-137Published: 23 December 2011
Additional file 1:
Peroxiredoxin 4 in clinical indications. This overview does not presume to be complete. Indeed, cited cancer settings are limited to subgroups with important clinical findings beyond changes in peroxiredoxin 4 expression. Unless otherwise mentioned, the term 'Prx4' refers to intracellular protein levels.
Format: DOC Size: 62KB Download file
This file can be viewed with: Microsoft Word Viewer